NCT00740155已完成2 期
Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 154
- 试验地点
- 2
- 主要终点
- Safety: To provide information concerning the safety of ChimeriVax™ Dengue Vaccine
研究概览
简要总结
This is part of an ongoing effort to develop a satisfactory dengue vaccine:
Primary objective:
To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates.
To describe the immune response after each vaccination of dengue vaccine.
详细描述
Subjects will be randomized to five groups to receive assigned vaccines and followed up for 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Safety: To provide information concerning the safety of ChimeriVax™ Dengue Vaccine
时间窗: 12 months post-vaccination
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in SingaporeDengue VirusDengue DiseasesDengue FeverDengue Hemorrhagic FeverNCT00880893Sanofi Pasteur, a Sanofi Company1,198
已完成
2 期
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy SubjectsDengue Hemorrhagic FeverDengue VirusDengue DiseaseDengue FeverNCT00875524Sanofi Pasteur, a Sanofi Company180
已完成
3 期
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in AsiaDengueDengue FeverDengue Hemorrhagic FeverNCT01373281Sanofi Pasteur, a Sanofi Company10,275
已完成
3 期
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®Dengue Hemorrhagic FeverHuman Papillomavirus DiseaseDengue FeverNCT02993757Sanofi Pasteur, a Sanofi Company528
终止
3 期
Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy SubjectsDengue Hemorrhagic FeverDengue FeverNCT02992418Sanofi Pasteur, a Sanofi Company688